RELATED PARTY TRANSACTIONS

9 Months Ended

Sep. 30, 2019

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS

NOTE 9—RELATED PARTY TRANSACTIONS

MSK is a shareholder of the Company. Under the MSK License Agreement, the CD33 License Agreement, CTA, CFAs, SRA and MDSA, we have expensed costs in the total amount of $1,384,000 and $914,000 in the three months ended September 30, 2019 and 2018, respectively, for milestones, minimum royalties, and research and development costs. We expensed costs in the total amounts of $5,307,000 and $4,526,000 in the nine months ended September 30, 2019 and 2018, respectively, under these agreements with MSK. Please refer to Note 6 for additional details on our agreements with MSK. As of September 30, 2019 and December 31, 2018, we had a total of $3,829,000 and $4,475,000, respectively, recorded as accounts payable and accrued liabilities related to amounts due to MSK.